Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lisdexamfetamine
Drug ID BADD_D02440
Description Also known as _Vyvanse_, lisdexamfetamine (L-lysine-d-amphetamine) is a prodrug of the psychostimulant d-amphetamine [A40246]. It is paired with the essential amino acid _L-lysine_. Lisdexamfetamine dimesylate increases attention span and decreases restlessness in children and adults who are overactive/hyperactive, cannot concentrate for long periods, or are easily distracted or impulsive [A2230]. As a central nervous system stimulant, lisdexamfetamine is utilized as an adjunct therapy in the treatment of attention deficit hyperactivity disorder (ADHD). As a prodrug, lisdexamfetamine was specifically engineered as an abuse-resistant product [F2368]. The mechanism by which this occurs is through delayed release after ingestion (unlike some other psychostimulant drugs, which may be abused). After oral administration and absorption, enzyme hydrolysis after contact with red blood cells metabolize lisdexamfetamine into L- lysine, a naturally occurring essential amino acid and active _d-amphetamine_, which is responsible for the drug’s pharmacological effects. Gastrointestinal pH does not affect this conversion, and the addition of the L-lysine slows the amount of d-amphetamine available in the circulation and central nervous system [F2368].
Indications and Usage For the treatment of Attention-deficit/hyperactivity disorder (ADHD) and for moderate to severe binge eating disorder in adults [FDA label], [A40246]. This drug is not indicated for weight loss. Use of other sympathomimetic drugs for weight loss is associated with serious cardiovascular effects. The safety and effectiveness of this drug for the treatment of obesity have not yet been determined [FDA label].
Marketing Status approved; investigational
ATC Code N06BA12
DrugBank ID DB01255
KEGG ID D08130
MeSH ID D000069478
PubChem ID 11597698
TTD Drug ID D00DEF
NDC Product Code Not Available
UNII H645GUL8KJ
Synonyms Lisdexamfetamine Dimesylate | Dimesylate, Lisdexamfetamine | Lis-dexamfetamine Dimesylate | Dimesylate, Lis-dexamfetamine | Lis dexamfetamine Dimesylate | Vyvanse | Elvanse | Lisdexamfetamine | NRP104 | NRP-104 | NRP 104
Chemical Information
Molecular Formula C15H25N3O
CAS Registry Number 608137-32-2
SMILES CC(CC1=CC=CC=C1)NC(=O)C(CCCCN)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Decreased appetite08.01.09.028; 14.03.01.0050.009457%
Erectile dysfunction21.03.01.007; 19.08.04.0010.001592%
Psychiatric symptom19.01.02.0010.000424%Not Available
Ill-defined disorder08.01.03.0490.000695%Not Available
Sensation of foreign body08.01.09.0020.000153%Not Available
Adjustment disorder19.23.01.0010.000070%Not Available
Adverse drug reaction08.06.01.0090.002336%Not Available
Psychotic disorder19.03.01.0020.000793%
Pigmentation disorder23.05.03.0010.000153%Not Available
Unevaluable event08.01.03.0510.005139%Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.000355%Not Available
Autism spectrum disorder19.22.02.002; 17.03.05.0030.000070%Not Available
Suicidal behaviour19.12.01.0060.000174%Not Available
Dermatillomania23.03.11.011; 19.06.05.0050.000223%Not Available
Substance abuse19.07.06.0180.000188%Not Available
Thyroid cancer16.24.03.001; 05.02.05.0010.000070%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.000814%
Substance-induced psychotic disorder19.03.01.007; 12.03.01.0530.000070%Not Available
Noninfective gingivitis07.09.13.0160.000236%Not Available
Irregular breathing22.02.01.0260.000070%Not Available
Frustration tolerance decreased19.04.02.0160.000473%Not Available
Abnormal loss of weight14.03.02.0190.000459%Not Available
Change in sustained attention19.21.02.0090.000306%Not Available
Coeliac disease14.02.01.007; 10.04.04.012; 07.17.01.0080.000243%Not Available
Grandiosity19.05.01.0190.000070%Not Available
Impulsive behaviour19.18.01.0010.001391%Not Available
Post-traumatic stress disorder19.06.06.0020.000223%Not Available
Social anxiety disorder19.06.03.0100.000153%Not Available
Tobacco abuse19.07.06.0210.000188%Not Available
Negative thoughts19.15.02.0120.000104%Not Available
The 9th Page    First    Pre   9 10    Next   Last    Total 10 Pages